Biotechs and Tech Lead The Way For 2016

DELRAY BEACH, FL / ACCESSWIRE / December 16, 2015 / As the door begins to close on 2015, investors seeking to build a strong foundation for 2016 will want to take a glance back at the most relevant industries heading into the new year, and to make moves accordingly. Small cap biostocks in particular made strides over the last couple of financial quarters, with Cannabis Science, Inc. (CBIS) standing out in recent weeks with several key distribution and development moves.

On Tuesday, Cannabis Science announced that it has entered into partnership with ImmunoClin (IMCL) to oversee all aspects of a new clinical research program for Cannabis Science. The intent with this program will be to place an emphasis on GMP quality pre-clinical data, a process that will include cultivation, formulation, and manufacturing of various strains of clinical grade cannibinoid products.

In addition to the innovation of this new program, Cannabis Bioscience has been busy diversifying its partnerships and business intent. Last week, the company entered a new, high-dosage product line of its CBD, Sativa, and Indica product capsules into an industry-leading event called Emerald Cup in Santa Rosa, California. The event should enhance exposure to Cannabis Bioscience’s product line by way of sampling, vender booths, presentations, and even various contests featuring cannabin products.

But Cannabis Bioscience, while focusing on the endeavor of clinical research and the diversification of its product capsule distribution, has also been at work on a line of Animal Care products released through the company’s recently acquired, wholly-owned subsidiary, Equi-Pharm LLC. Thanks to this move and others, such as Cannabis Bioscience’s retention of I-Business Management for the purposes of investor and public relations as well as corporate and product branding, industry analysts have begun to raise projections for the company’s stock.

Americans spent an all-time high of over $55 billion on their pets last year, a market that Cannabis Bioscience plans on tapping into with its animal healthcare product line. Thus, on the basis of these products and the company’s recent progress, a new independent report placed long-term projections for the company’s stock at approximately 10 times its current value.

Another biotech worth investigating is TapImmune, Inc. (TPIV). Recent data revealed at the San Antonio Breast Cancer Symposium revealed that treatment with the company’s flagship drug, TPIV 100, significantly boosts T-cell immunity in patients, meaning the drug could be useful in prevention of disease recurrence or for tumor regression when used prior to surgery, among other uses. Company CEO Dr. Glynn Wilson indicated that these findings were promising enough to begin Phase II clinical trials with the drug.

Encouraging recent news was also unveiled for Amarantus Bioscience (AMBS), a biotech working on specially formulated biologics for Parkinson’s. The company received a notice of allowance for a U.S. patent application to enhance IP protection for eltoprazine, the company’s leading candidate for treating elodea-induced dyskinesia in Parkinson’s patients.

LabStyle Innovations (DRIO) also has enjoyed a recent upswing from buzz over its flagship product, the Dario™ Blood Glucose Monitoring System. This system allows diabetics to monitor their blood glucose levels via their smart phone devices, while also providing tracking and treatment tools through website and phone applications. This data can be viewed by the patient’s doctors or family members to enhance care and treatment. Using a multi-pronged revenue approach via sales of the application, glucose strips, and other software services, LabStyle forecasts as a stock to watch thanks to so much upside from revenue potential and uniqueness of brand.

As the New Year approaches, small cap biotech stocks have emerged as a prime candidate for investors looking to catch small cap stocks with the potential for huge upside. Cannabis Bioscience in particular has demonstrated a willingness to participate in acquisitions and diversification that could trigger company growth for years to come.

Seraphim Strategies is a third party publisher. Not a registered broker/dealer/analyst/adviser, holds no investment licenses and may not sell, offer to sell or offer to buy any security. Market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is not to be interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. For full disclaimer please read http://tomorrowsbluechips.com/disclaimer/ This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

“Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

SOURCE: Seraphim Strategies LLC

ReleaseID: 434787